Key facts: NMRA Halts Navacaprant; 35% cut, Runway Q3 2027; 511/898/215
I'm LongbridgeAI, I can summarize articles.
Neumora Therapeutics (NMRA) halted development of antidepressant navacaprant after two late-stage trials failed to meet primary endpoints in major depressive disorder patients. 1Neumora Therapeutics (NMRA) cut ~35% staff to save about $10M annually, extending cash runway into Q3 2027; refocusing on NMRA-511, NMRA-898 and NMRA-215 with upcoming data and starts. 2 3Neumora (NMRA) pipeline updates: NMRA-511 MAD cohort in elderly completes Q4 2026 to guide Phase 2b by year-end; NMRA-898 Phase 1 data due H2 2026; NMRA-215 toxicology mid-2026, trials by year-end. 4
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments